



Are you living with Progressive Pulmonary Fibrosis (PPF)?

If so, you may be eligible for a clinical research study. The IM0271015 (ALOFT-PPF) study is testing an investigational drug called BMS-986278 (the “study drug”) as a potential new treatment for PPF.

Treatments available today can help, but for some people PPF gets worse despite treatment¹. There is a need for continued research to identify potential new treatments.

About the ALOFT-PPF study

This clinical research study is evaluating the study drug to learn more about its:

- Safety
- Tolerability (how the body reacts)
- Effect on PPF progression

You may qualify to participate in this study if you:

- Are 21 years of age or older
- Have been diagnosed with pulmonary fibrosis that has an identifiable cause and has progressed (gotten worse) or is at high risk of progression
- Have not had lung reduction surgery or lung transplantation within the past 12 months
- Do not have plans to undergo lung reduction surgery or lung transplantation within the next 12 months

Additional eligibility requirements will be checked as part of study screening.

If you qualify and choose to participate, you will NOT be charged for the study drug, visits, tests, and procedures necessary for the study per the study protocol. Participation is voluntary; you will be free to stop at any time.

To learn more about the ALOFT-PPF study, please contact:

[site contact information]

¹ Flaherty KR, Wells AU, Cottin V, et al. Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. N Engl J Med. 2019;381(18):1718-27.